Ron Kurtz

“Over the last several years, the RxSight team has been developing proprietary hybrid IOL materials for next-generation light-adjustable technology that can support a full suite of adjustable lenses across all premium categories.”

“Yeah, I think that, you know, if we go back to introduction, really, when we started to, after our IPO in 21, we saw a steady and then fairly rapid adoption to where we, you know, on a volume basis, have come up to about 10% of the overall premium market by volume, about 15% by revenue.”

“I'd like to start by both welcoming Mark to his first RxCite earnings call and asking him to kick us off today by reviewing our fourth quarter and full year 2025 financial results, including the key drivers of performance and the trends across the business.”

“During the third quarter, we've made meaningful progress strengthening our commercial execution in the U.S. while laying the groundwork for our broader global growth.”

“I want to first recognize the entire RxSight team as well as our partners in clinical practice for all of their efforts to provide high-quality customized vision to patients undergoing cataract surgery.”